Accelerate Your Small Molecule Drug Discovery With X-Chem

A leader in small molecule drug discovery and the DNA-encoded library (DEL) technology pioneer, X-Chem combines proven DEL and medicinal chemistry expertise with groundbreaking AI solutions. Unlock the power of your data and accelerate from hit-to-lead to candidate.

ArtemisAI Accelerate Discovery

Generate More Hits Faster

X-Chem’s proprietary ArtemisAI uses a suite of machine learning models paired with extensive DEL data to revolutionize the discovery of new medicines and realize the full potential of rich datasets.

More About ArtemisAI

What Our Clients Are Saying

“With the cutting-edge technology offered by X-Chem and our knowledge of dermatology, we will be able to broaden our pipeline and provide further medical solutions for physicians and patients, specially designed for dermatological diseases with unmet needs.”

Bhushan Hardas Chief Scientific Officer, Almirall

“We are excited to expand our collaboration with X-Chem, focusing on the synthesis and delivery of custom libraries as well as the transfer of the DEX™ platform in-house, an important pillar of our small molecule discovery strategy.”

Sir Mene Pangalos Executive Vice President, Early Discovery Research, AstraZeneca

“We anticipate that our drug discovery research will be further enhanced through X-Chem’s breakthrough technology, leading to the creation of breakthrough pharmaceuticals.”

Toshiki Sudo Executive Director of Research and Intellectual Property, Otsuka

“As we tackle new targets, we have been very impressed with X-Chem’s technology platform and what it has delivered in the first 18 months of our partnership. Based on that success, we are eager to extend our work with X-Chem to additional targets for serious diseases.”

Mark Bunnage Senior Vice President and Boston Research Site Head, Vertex

80% Success Rate in Identifying Functional Hits

Nearly 100 Programs Licensed

Proven in 30 Challenging Target Classes

4 Clinical candidates in 2021